about
Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatinRoles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataHMG-CoA reductase inhibitors and P-glycoprotein modulationAdherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register studyA clinical therapeutic protein drug-drug interaction study: coadministration of denosumab and midazolam in postmenopausal women with osteoporosis.Statin drug interactions and related adverse reactions.Aggressive lipid management for cardiovascular prevention: evidence from clinical trials.Antihypertensive therapy: special focus on drug interactions."Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein.Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling.Role of P-glycoprotein in statin drug interactions.Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition.Simvastatin interactions with other drugs.Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.Drug interactions with statins.Impact of pharmacists' interventions and simvastatin dose restrictions.Drug-drug interaction with statins.Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects.Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.The influence of high-dose simvastatin and diltiazem on myocardium in rabbits: a haemodynamic study.Effects of concomitant therapy with diltiazem on the lipid responses to simvastatin in Chinese subjects.Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia.Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
P2860
Q24679132-C27BB4C1-A222-4186-A2DB-4F824D2008FFQ25255438-E314A6BD-B3C1-4838-9E8D-88BBBA1E4FE5Q27009128-46626528-A67A-4FD3-85BB-90FCC7F76F7DQ28360140-B503D181-DBC7-487D-AFC4-BE9A744E8E05Q28535157-19B88CD0-1E29-481D-B8C7-9036463F140BQ34286862-D76630CE-CCBA-4216-81CE-4CA274652C36Q34292468-890214E9-9E8A-4657-9573-22E81E5B9DF7Q35183108-4E76F8A0-3F61-41F5-861E-49645F49F0C6Q35570981-2AF04235-86F7-42E9-9B1E-D5D808D721D5Q35640730-35D5E55D-689E-41E9-9EE3-2C920D1E7942Q35826861-91B83061-9929-41A6-A32B-0E6EBF6A8238Q36558235-FD8B429B-12B4-4AC9-8FA0-BEF7AE938716Q36629237-8EB6419A-ACA9-4984-A8DB-CD76EE7F7D42Q36634221-64E5087F-F6C0-47CB-A851-9DE916897580Q37440022-192C229B-1C2D-4790-83C7-C03F992FA928Q37872364-8877EFCC-AA4B-4BCA-AF74-A4A8A1960770Q37993600-E4897DD7-4B04-494E-A320-7D34F2BCFF27Q38099049-1E4403FA-D7DB-4A73-B66A-8A4FB51F2E60Q38155016-6DF00360-F2A1-45B4-8CDA-5BB1CE698A81Q38164673-7AF38A6E-0157-4A26-BD2C-45FAD2811B70Q38177333-033DABCB-1587-47D1-A2D7-E9307F7482FCQ38707185-90EC1C8A-A9D2-45DF-BA44-CEBEEA1B525DQ39472689-0D535881-967B-4106-8BAE-74774ADA4DB3Q39516917-F413A758-3AFB-449B-87B8-3D45D11A19F4Q40415948-D871C974-9462-446A-968C-5E5425A4D40DQ43164707-CC20EE1D-A79A-496C-A7F6-5817BE038B87Q43826505-3F535685-411B-4594-82F1-74243E82057DQ44137319-978396CE-660A-470E-874F-B12530F27EA7Q44803518-51F0F6F7-B1BA-48CD-BEF1-6579779EAF6DQ46391221-90933DD7-88DB-41D6-A594-C63E7B50D9CCQ53848245-11C8B724-8786-45C0-BED2-36378D7B8DF5Q54235749-BB8F4FEE-3628-4E4B-A980-742E6C8BD08D
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մարտին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The interaction of diltiazem with simvastatin
@ast
The interaction of diltiazem with simvastatin
@en
The interaction of diltiazem with simvastatin
@nl
type
label
The interaction of diltiazem with simvastatin
@ast
The interaction of diltiazem with simvastatin
@en
The interaction of diltiazem with simvastatin
@nl
prefLabel
The interaction of diltiazem with simvastatin
@ast
The interaction of diltiazem with simvastatin
@en
The interaction of diltiazem with simvastatin
@nl
P2093
P356
P1476
The interaction of diltiazem with simvastatin
@en
P2093
P304
P356
10.1067/MCP.2000.104609
P407
P577
2000-03-01T00:00:00Z